Etiopatogenia da Doença de Parkinson
DOI:
https://doi.org/10.34024/rnc.2005.v13.8794Palavras-chave:
Doença de Parkinson, Etiologia, Genética, AmbienteResumo
Pesquisas recentes têm demonstrado que a Doença de Parkinson (DP) deve ser considerada como uma enfermidade neurodegenerativa, progressiva, caracterizada pela presença de disfunção monoaminérgica múltipla, incluindo o déficit de sistemas dopaminérgicos, colinérgicos, serotoninérgicos e noradrenérgicos. Outros sinais da DP são os chamados não-motores (como os distúrbios do sono, a disfunção cognitiva, a depressão) e podem estar relacionados com o acometimento de diferentes áreas do tronco cerebral de diferentes regiões do cérebro. Nesse estudo, o autor faz uma revisão atual sobre a etiopatogenia da doença de Parkinson, enfatizando as hipóteses genética e ambiental.
Downloads
Métricas
Referências
Olanow CW, Jenner P, Tatton NA, Tatton WG. Neurodegeneration and Parkinson’s disease. In: Jankovic J, Tolosa E. Parkinson’s disease and Movement Disorders. Third edition. Baltimore: Williams & Wilkins, 1998; 67-103.
Mizuno Y, Ikebe SI, Hattori N, et al. Etiology of Parkinson’s disease. In Watts RL, Koller WC (eds). Movement Disorders. Neurologic Principles and Practice. New York: McGraw-Hill, 1997, 161-182.
Gibb WRG, Lees AJ. Pathological clues to the cause of Parkinson’s disease. In: Marsden CD, Fahn S (eds). Movement Disorders 3. Oxford: Butterworth-Heinemann Ltd., 1994, 145-166.
Golbe LI, Langston JW. The etiology of Parkinson’s disease: New directions for research. In: Jankovic J, Tolosa E (eds). Parkinson’s disease and Movement disorders, second edition. Baltimore: Williams & Wilkins, 1993, 93-101.
Teive HAG. Etiopatogenia da Doença de Parkinson. In: Meneses MS, Teive HAG (eds). Doença de Parkinson. Rio de Janeiro: Guanabara-Koogan, 2003, 33-37.
Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson´s disease. Neurobiol Aging 2003; 24: 197-211.
Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson’s disease. Brain 2000; 123: 1767-1783.
McKaught KSP, Olanow CW. Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson´s disease. Ann Neurol 2003; 53(suppl 3) : S73-S86.
McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002; 16: 2136-2148.
Lucking CB, Brice A. Alpha-synuclein and Parkinson’s disease. Cell Mol Life Sci 2000; 57: 1894-1908.
Maraganore DM, de Andrade M, Lesnick TG, et al. Complex interactions in Parkinso´s disease: A two-phased approach. Mov disord 2003; 18: 631-636.
Surguchov A, Surgucheva I, Solessio E, Baehr W. Synoretin - A new protein belonging to the synuclein family. Mol Cell Neurosci 1999; 13: 95-103.
Engelender S, Kaminsky Z, Guo X, et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genent 1999; 22: 110-114.
Nussbaum RL, Ellis CE. Azheimer´s disease and Parkinson´s disease. N Engl J Med 2003; 348: 1356-1364.
Rawal N, Periquet M, Lohmann E, et al. New parkin mutations an atypical phenotypes in families with autosomal recessive parkinsonism. Neurology 2003; 60: 1378-1381.
Rawal N, Periquet M, Lohmann E, et al. Park gene analysis in early-onset parkinson’s disease. Brain 2002;126: 1271-1278.
McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Slective loss of 20S proteosome alpha-subunits in the substantia nigra pars compacta in Parkinson´s disease. Neurosci Lett 2002; 326: 155-158.
Logroscino G, Marder K, Graziano J, et al. Dietary iron, animal fats and risk of Parkinson’s disease. Movement Disorders 1998; 13 (suppl.1): 13-16
Racette BA, McGee-Minnich L, Moerlein SM, Mink JW, Videen TO, Perlmutter JS. Welding-related parkinsonism. Clinical features, treatment, and pathophysiology. Neurology 2001; 56: 8-13.
Rieder CRM. Papel dos tóxicos ambientais. In: Meneses MS, Teive HAG. Doença de Parkinson. Rio de Janeiro: Guanabara Koogan, 2003, 42-49.
Ballard PA, Tetrud JW, Lagnston JW. Permanent human Parkinsonism due to 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) : Seven cases. Neurology 1985; 35:949-956.
Racette BA, Tabbal SD, Jennings D, et al. Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology 2005; 64: 230-235.
Josephs KA, Ahlskog JE, Klos HJ, et al. Neurologic manifestations in welders with pallidal MRI T1 hyperintensity. Neurology 2005; 64: 2033-2039.
Jankovic J. Searching for a relationship between manganese and welding and Parkinson´s disease. Neurology 2005; 64: 2021-2028.
Jenner P. Oxidative mechanisms in nigral cell death in Parkinson’s disease. Movement Disorders 1998; 13 (suppl 1): 24-34.
Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson’s disease: Evidence supporting it. Ann Neurol 1992;32: 804-812.
Calne DB. The free radical hypothesis in idiopatic Parkinsonism: Evidence against it. Ann Neurol 1992; 32:799-803
Agid Y. Levodopa. Is a toxicity a myth? Neurology 1998; 50: 858-863.29. Rajput AH, Fenton Me, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra ? Mov Disord 1998; 12:369-370.
Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson’s disease. Neurobiol Dis 2000; 7: 240-250.
Hirsch EC, Faucheux BA. Iron Metabolism and Parkinson’s disease. Movement Disorders 1998; 13 (suppl 1): 39-45.
Castellani RJ, Siedlak SL, Perry G, Smith MA. Sequestration of iron by Lewy bodies in Parkinson’s disease. Acta Neuropathol (Berl) 2000; 100: 111-114.
Curtis AR, Fey C, Morris CM, et al. Mutation in the gene enconding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat genet 2001; 28: 350-354.
Chen R, Langston JW, Chan P. Screening of ferritin light polypeptide 460-461InsA mutation in Parinson’s disease patients in North America. Neurosci Lett 2002; 335: 144-146.
Burke RE. Programmed cell death and Parkinson’s disease. Movement Disorders 1998; 13 9suppl 1): 17-23.
Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. French Parkinson’s Disease Genetics Study Group. N Engl J Med 2000; 342 : 1560-1567.
Vaughan JR, Davis MB, Wood NW. Genetics of parkinsonism: a review. Ann Hum Genet 2001; 65: 111-116.
Gasser T. Molecular genetics of Parkinson’s disease. Adv Neurol 2001; 86: 23-32.
Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson’s disease. JAMA 2001; 286: 2239-2244, 2245-2250.
Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisan RC. A large kindred with autosomal dominant Parkinson’s disease. Ann Neurol 1990; 27: 276-282.
Markopoulou K, Wszolek ZK, Pfeiffer RF. A greek-American kindred with autosomal dominant levodopa-responsive parkinsonism and antecipation. Ann Neurol 1995; 38: 373-378.
Golbe L, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson’s disease in the Contursi kindred. Ann Neurol 1996; 40:767-775.
Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for parkinson’s disease to chromosome 4q21-23. Science 1996; 274: 1197-1199.
Polymeropoulos MH, Lavedant C, Leroy E, et al. Mutation in the @-synuclein identified in families with Parkinson’s disease. Science 1997; 276:2045-2047.
Heintz N, Zoghbi H. Alpha-Synuclein - a link between Parkinson and Alzheimer diseases? Nature genetics 1997;16: 325-327.
Chan P, Jiang X, Forno LS, Di Monte DA, Tanner CM, Langston JW. Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson’s disease. Neurology 1998; 50: 1136-1137.
Chan P, Tanner CM, Jiang X, Forno LS, Di Monte DA, Lagnston JW. Absence of mutation in the alfa-sinucleína gene in clinically-and pathologically defined Parkinson’s disease. Neurology 1998; 50 (suppl 4): A197.
Lynch T, Neystat M, Orvis L, et al. Normal alphasynuclein gene sequence in 21 autosomal dominant Parkinson’s disease families. Neurology 1988; 50 (suppl 4): A197.
Nelson LM, Chan P, Tanner CM, Van Den Eeden SK. Absence of the alfa-synuclein gene missense mutation (G209A) in 40 patients with a family history of Parkinson’s disease. Neurology 1998; 50 (suppl 4): A197.
Scott WK, et.al. Exclusion of the alpha-synuclein gene as a major genetic risk factor in idiopathic Parkinson’s disease (PD). Neurology 1998; 50 (suppl 4): A356-A357.
Papadimitriou A, Veletza V, Anastasopoulos I, Patrikiou A, Hadjigeorgiou GM. Alpha-synuclein gene mutation (G209A) in Greek kindreds with familial Parkinson’s disease. Neurology 1998; 50 (suppl.4): A356.
Teive HAG, Raskin S, Iwamoto FM, et al. The G209A mutation in the @-synuclein gene in brazilian families with Parkinson’s disease. Arq Neuropsiquiatr 2001; 59: 722-724.
Matsumine H, Saito M, Shimoda-Matsubayashi S, et al. Localization of a gene for na autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997; 60: 588-596.
Matsumine H, Yamamura Y, Kobayashi T, Nakamura S, Kuzuhara S, Mizuno Y. Early onset Parkinsonism with diurnal fluctuation maps to a locus for juvenile Parkinsonism Neurol 1998; 50: 1340-1345.
Choi P, Ostrerova-Golts N, Sparkman D, Cochran E, Lee JM, Wolozin B. Parkin is metabolized by the ubiquitin/proteosome system. Neuroreport 2000; 11: 2635-2638.
Chung KK, Zhang Y, Lim KL, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy body formation in Parkinson disease. Nat Med 2001; 7: 1144-1150.
Lohmann E, Periquet M, Bonifati V, et al. Are the phenotype-genotype correlation in Parkin patients? Ann Neurol 2003; 54: 176-185.
Iwamoto FM, Teive HAG, Raskin S, et al. Parkin gene mutations in Brazilian patients with Parkinson´s disease. Parkinsonism and Related Disorders 2005; (enviado para publicação).
Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, et al. Novel parkin mutations detected in patients with early-onset Parkinson´s disease. Mov Disord 2005; 20: 424-431.
Valente EM, Brancati F, Caputo V, et al. Park 6 is a commom cause of familial parkinsonism. Neurol Sci 2002; Suppl 2: S117-118.
Bonifati V, Rohe CF, Breedveld GJ, et al.. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005; 65: 87-95.
Bonifati V, Rizzu P, van Baren MJ, et al. Mutations inthe DJ1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
Paisan-Ruiz C, Saenz A, Lopez de Murian A, et al. Familial Parkinson´s disease: clinical and genetic analysis of four Basque families. Ann Neurol 2005; 57: 365-372.
Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson´s disease. Lancet 2005; 365: 412-415.
Bonifati V, Dekker MC, Vanacore N, et al. Autosomal recessive early-onset parkinsonism is linked to three loci: Park2, Park6 and Park7.
Goldman S, Tanner C. Etiology of Parkinson’s disease. In: Jankovic J, Tolosa E (eds). Parkinson’s disease and Movement disorders, third edition. Baltimore: Williams & Wilkins, 1998, 133-158.
Payami H, Lee N, Zareoarsi S, et al. Parkinson’s disease, CYP2DL, and age. Neurology 2001; 56: 1363-1370.
Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson’s disease. Lancet 1997; 350: 1136-1139.
Wilhelmsen K, Mirel D, Marder K, et al. Is there a genetic susceptibility locus for Parkinson’s disease on chromosome 22q13? Ann Neurol 1997; 41: 813-817.
Riedl AG, Watts PM, Jenner P, Marsden CD. P450 enzymes and Parkinsons’s disease: The story so far. Mov Disord 1998; 13: 212-220.
Pang Cp, Zhang J, Woo J, et al. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson’s disease. Movement Disorders 1998; 13: 529-532.
Wooten GF, Currie LJ, Bennett JP, Harrison MB, Trugman JM, Parker Jr WD. Maternal inheritance in Parkinson’s disease. Ann Neurol 1997; 41: 265-268.
Wood N. Genes and Parkinsonism. J Neurol Neurosur Psychiatr 1997; 62: 305-309.
Teive HAG, Raskin S. Aspectos genéticos da doença da doença de Parkinson. In: Meneses MS, Teive HAG. Doença de Parkinson. Rio de Janeiro: Guanabara Koogan, 2003, 38-41.
Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson´s disease (PARk 8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51: 296-301.
Feany MB, Bender WW. A Drosophila model of Parkinson’s disease. Nature 2000; 404: 394-398.
Beal MF. Experimental models of Parkinson’s disease. Nat Rev Neurosci 2001; 5: 325-334.
Muqit MM, Feany MB. Modeling neurodegenerative diseases in Drosophila: a fruitful approach? Nat Rev Neurosci 2002; 3: 237-243.
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2005-12-31
Português
English
Español
